Interventions for Tuberculosis Control and Elimination 2002

1083. Perumal VK, Gangadharam PRJ, Iseman MD. Effect of rifabutin on the phagocytosis
and intracellular growth of Mycobacterium intracellulare in mouse resident
and activated peritoneal and alveolar macrophages. Am Rev Respir Dis
1987; 136: 334-7.
1084. Perumal VK, Gangadharam PRJ, Heifets LB, Iseman MD. Dynamic aspects of
the in vitro chemotherapeutic activity of ansamycin (rifabutine) on Mycobacterium
intracellulare. Am Rev Respir Dis 1985; 132: 1278-80.
1085. O’Brien RJ, Geiter LJ, Lyle MA. Rifabutin (ansamycin LM427) for the treatment
of pulmonary Mycobacterium avium complex. Am Rev Respir Dis 1990;
141: 821-6.
1086. Hong Kong Chest Service, British Medical Research Council. A controlled
study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of
patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and
rifampicin. Tubercle Lung Dis 1992; 73: 59-67.
1087. McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK,
Fourie PB. Efficacy and safety of rifabutin in the treatment of patients with
newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996;
154: 1462-7.
1088. Gonzalez Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the
treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized,
comparative study versus rifampicin. Tubercle Lung Dis 1994; 75: 341-7.
1089. Schwander S, Rüsch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C,
Rubaramira R, Mugyenyi P, Okwera A, Mugerwa R, Aisu T, Moser R, Ochen K,
M’Bonye B, Dietrich M. A pilot study of antituberculosis combinations comparing
rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis.
Tubercle Lung Dis 1995; 76: 210-8.
1090. Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, Allen BW,
Mitchison DA. The early bactericidal activity of rifabutin measured by sputum
viable counts in Hong Kong patients with pulmonary tuberculosis. Tubercle
Lung Dis 1992; 73: 33-8.
1091. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin
Infect Dis 1996; 22(suppl 1): S15-S22.
1092. Bendetti MS. Inducing properties of rifabutin, and effects on the pharmacokinetics
and metabolism of concomitant drugs. Pharmacol Res 1995; 32: 177-87.
1093. Narita M, Stambaugh JL, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use
of rifabutin with protease inhibitors for human immunodeficiency virus-infected
patients with tuberculosis. Clin Infect Dis 2000; 30: 779-83.
1094. Mancini P, Pasqua F, Mazzei L, Olliaro P. Rifabutin treatment for tuberculosis
patients with liver function abnormalities. (Correspondence). J Antimicrob
Chemother 1992; 30: 242.
242